The administrative component of this PSO (PPG) will have both scientific and organizational responsibilities. This Program Project will involve four interrelated research projects supported by two core facilifies. Dr. Breakefield will serve as the Program Director and liaison between laboratories. She will be assisted in administrative responsibilities by an experienced Grants manager, Ms. Robin Sobolewski. Dr. Breakefield will make all final decisions on the operations of the PSO after extensive discussions with involved individuals. Dr. Breakefield will be advised by an Internal Advisory Committee consisting of three senior members of the PPG: Dr. Pradeep Bhide, Dr. David Standaert and Dr. Laurie Ozelius, as well as two invesfigators at Partners (MGH/BWH) with related expertise - Dr. James Gusella (human genetics and neurologic disease) and Dr. David Kwiatkowski (mouse models for neurologic disease and cell biology). Combination conference calls/onsite meetings will be held at least twice a year with this group as issues arise needing advice. This group will also be present at the External Advisory meeting. The functions of this committee will consist of critical review of key data, strategic guidance in planning future experiments and collaborations, advice on any conflicts that arise within the PPG group or with collaborators, and appropriate adjustments resulting from any changes in Pl status or their locations. Patient issues will be handled by the physician/scientists in the group, Drs. Nutan Sharma and David Standaert, as well as our collaborator. Dr. Susan Bressman, with genefic counseling issues covered by Drs. Sharma and Bressman, with assistance from Ms. Trisha Multhaupt-Buell, a Genetic Counselor in the Movement Disorder Clinic. Advice on research strategy and evaluation of progress will be undertaken in consultation with a standing External Advisory Committee on a yearly basis at a day-long meeting at MGH. This committee will consist of five individuals (two, James Gusella and David Kwiatkowski also serving as members of the Internal Advisory Committee) with combined expertise in human genetics, neuronal development, cell biology, mouse models and clinical aspects of dystonia. (According to NINDS guidelines the additional names of members of the committee and letters from them will be provided when the application is funded). A detailed progress report incorporafing critiques from the external review prepared by the External Advisors and Internal non-PPG Advisors will be distributed to all investigators in the Center and incorporated into the progress report of the non-competitive confinuation applications. The scientific oversight will be carried out primarily by Dr. Breakefield, who will advise investigators on strategic and technical issues, promote collaboration among projects, monitor the functions and effectiveness of core facilities, and assess the scientific quality and progress of the work. This will require active interactions with all groups. Dr. Breakefield will confer with other members of the PSO on a weekly/monthly basis through informal discussions of progress and strategy via direct contact (Drs. Bhide, Sharma and Breakefield are located in adjacent space at MGH), phone calls, e-mail, tri-annual internal PSO meetings spread throughout each year, the annual External Advisor review and other national/international meetings attended by subsets of this group. In the annual progress reports we will include all interactions among Pis and collaborators in this PPG, as well as all attendees at the internal PPG meetings and External Reviews. To make sure there is ongoing exchange among Pis in the Northeast and Dr. Standaert in Georgia, in addition to the common meetings attended by Dr. Standaert and other Pis in this group, as well as biannual conference calls of the Internal Advisory Committee, we now plan to institute a monthly conference call among all Pis with exchange of data images using internet based technology for slide sharing (Glance.net). Through her close contacts with all the participants in this Center, Dr. Breakefield will be able to stimulate collaborative interactions and resolve potential conflicts before they arise. Given the high creativity and productivity of the investigators, their natural tendency to collaborate and their long track record of interaction and commitment to dystonia research, her main job will be to promote communication of research findings and sharing of reagents/resources within and among outside groups, and to guide investigators toward common foci and goals. Organizational aspects will be handled by Dr. Breakefield's administrative co-ordinator, Ms. Robin Sobolewski. These aspects will include setting up meetings, distributing memos and notices, assembling internal and external reports and interacting with administrators working for the other investigators at MGH, UAB and Mt. Sinai. Administrative issues that will be handled by both Dr. Breakefield and Ms. Sobolewski include rebudgeting of funds, changes in personnel, issues of indirect cost rates, and input into institutional space allocations. They will prepare all progress reports and applications related to this Program Project. Dr. Breakefield has had extensive administration experience. She served as Director of the Molecular Neurogenetics Division at the Shriver Center for over four years. She has directed a NINDS Program Project grant on """"""""Molecular Genetics of Inherited Neurological Diseases"""""""" s nce it commenced funding in 1987 and has been actively involved at her institution and nationally in reviewing clinical gene therapy protocols. She serves on the Board of Directors of the American Society of Gene Therapy, on the Scientific Advisory Board of the Bachmann-Strauss Dystonia - Parkinson Research Foundation, on an NINDS Study Secfion (NSD-B) and as an advisor in the Cure Dystonia Inifiative ofthe Dystonia Medical Research Foundafion. Her primary research Interest has been in dystonia since 1981 and during that fime she has interacted and collaborated with many scientists in this field which provides a nexus of information and resources for the current research efforts by this group. Ms. Robin Sobolewski has had over 16 years training and experience in business, and medical and scientific management, including administrative and fiscal management of two NIH POIs and many R01/R21s and foundation grants. Dr. Breakefield and Ms. Sobolewski work in neighboring offices at MGH-East. Ms. Sobolewski's office space is equipped with a Hewlett Packard (with links to MGH investigators and other collaborators, and reference database and search programs), a laser-jet printer, and a copy machine. Dr. Breakefield will devote 10% of her effort and Ms. Sobolewski 33% to this administrative core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS037409-11
Application #
8149947
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
11
Fiscal Year
2010
Total Cost
$106,360
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Litvan, Irene; Lees, Peter S J; Cunningham, Christopher R et al. (2016) Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord 31:644-52
de Gusmão, Claudio M; Fuchs, Tania; Moses, Andrew et al. (2016) Dystonia-Causing Mutations as a Contribution to the Etiology of Spasmodic Dysphonia. Otolaryngol Head Neck Surg 155:624-8
de Carvalho Aguiar, Patricia; Borges, Vanderci; Ferraz, Henrique Ballalai et al. (2015) Novel compound heterozygous mutations in PRKRA cause pure dystonia. Mov Disord 30:877-8
Nery, Flávia C; da Hora, Cintia C; Yaqub, Uzma et al. (2015) New methods for investigation of neuronal migration in embryonic brain explants. J Neurosci Methods 239:80-4
Yokoi, Fumiaki; Dang, Mai T; Liu, Jun et al. (2015) Decreased dopamine receptor 1 activity and impaired motor-skill transfer in Dyt1 ?GAG heterozygous knock-in mice. Behav Brain Res 279:202-10
Vaughn, Lauren S; Bragg, D Cristopher; Sharma, Nutan et al. (2015) Altered activation of protein kinase PKR and enhanced apoptosis in dystonia cells carrying a mutation in PKR activator protein PACT. J Biol Chem 290:22543-57
Yokoi, Fumiaki; Chen, Huan-Xin; Dang, Mai Tu et al. (2015) Behavioral and electrophysiological characterization of Dyt1 heterozygous knockout mice. PLoS One 10:e0120916
Eskow Jaunarajs, K L; Bonsi, P; Chesselet, M F et al. (2015) Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Prog Neurobiol 127-128:91-107
Nery, Flavia C; Atai, Nadia A; da Hora, Cintia C et al. (2014) Microfluidic platform to evaluate migration of cells from patients with DYT1 dystonia. J Neurosci Methods 232:181-188
Hettich, Jasmin; Ryan, Scott D; de Souza, Osmar Norberto et al. (2014) Biochemical and cellular analysis of human variants of the DYT1 dystonia protein, TorsinA/TOR1A. Hum Mutat 35:1101-13

Showing the most recent 10 out of 58 publications